EUVIMEDOpdag EUVIMED
Open access

A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer

Jenny Högström iD, Hanna M Doh iD, Aidan Kump iD, Boryana Petrova iD, Peng Wang iD, Jonathan D Lee iD, Kaisa Koivula iD, Nina Kozlova iD, Kayla A Cruz iD, Su Min Hong iD, Camila Perea iD, Arjun Garg iD and 8 more

Science Advances · 2026

DOI: 10.1126/sciadv.aef1145 ↗

At a glance

Journal article in Science Advances, 2026. Written by Jenny Högström and 19 co-authors. Institution: Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Major MEDLINE topics: Cyclin-Dependent Kinase 4, Breast Neoplasms, Drug Resistance, Neoplasm, Cyclin-Dependent Kinase 6. 59 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, National Institutes of Health, American Association for Cancer Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Resistance to standard-of-care therapies remains a major clinical challenge in the treatment of the most common breast cancer, the hormone receptor–positive (HR+) subtype. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors improve outcomes in early-stage HR+ disease, yet many patients relapse. Resistance mechanisms of relapsed tumors include genetic alterations, but in many cases, no genetic drivers are identified. Here, we investigated mechanisms underlying resistance to CDK4/6 inhibitors using breast cancer patient–derived models and tumors. We identified an unexpected, noncanonical nuclear function of fumarylacetoacetate hydrolase (FAH), an enzyme in the tyrosine catabolism pathway, as a driver of resistance. FAH translocated to the nucleus upon CDK4/6 inhibition, where it interacted with cyclin-dependent kinase 9 (CDK9), and promoted resistance. Nuclear FAH was enriched in tumors from relapsed patients, and inhibition of CDK9 reversed FAH-mediated resistance. These findings establish nuclear FAH as a biomarker of resistance and revealed CDK9 as a therapeutic vulnerability in CDK4/6 inhibitor–resistant HR+ breast cancer.

Subjects

MeSH terms (MEDLINE)

Cyclin-Dependent Kinase 4Breast NeoplasmsDrug Resistance, NeoplasmCyclin-Dependent Kinase 6Protein Kinase InhibitorsHydrolasesHumansFemaleAnimalsCell Line, TumorCyclin-Dependent Kinase 9TyrosineMice

Substances

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsHydrolasesCyclin-Dependent Kinase 9CDK4 protein, humanCDK6 protein, humanTyrosineCDK9 protein, human

Authors and institutions

  • Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Department of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Core Facilities, Medical University of Vienna, Vienna, Austria.
  • Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Physiology and Biophysics, University of Illinois Cancer Center, University of Illinois College of Medicine, Chicago, IL, USA.
  • Department of Pathology, and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA.

ORCID profiles: Jenny Högström, Hanna M Doh, Aidan Kump, Boryana Petrova, Peng Wang, Jonathan D Lee, Kaisa Koivula, Nina Kozlova, Kayla A Cruz, Su Min Hong, Camila Perea, Arjun Garg, Michal Weitman, Conor L Evans, Jonathan L Coloff, Gerburg M Wulf, Naama Kanarek, Taru Muranen

Funding

  • NCI NIH HHS
  • National Institutes of Health
  • American Association for Cancer Research
  • Breast Cancer Research Foundation
  • Harvard Stem Cell Institute
  • Hope Funds for Cancer Research
  • Croucher Foundation
  • Sigrid Juselius Foundation

Cite

APA

Högström, J., Doh, H. M., Kump, A., Petrova, B., Wang, P., Lee, J. D., Koivula, K., Kozlova, N., Cruz, K. A., Hong, S. M., Perea, C., Garg, A., Weitman, M., Evans, C. L., Coloff, J. L., Patel, J. M., Wulf, G. M., Collins, L. C., Kanarek, N., & Muranen, T. (2026). A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer. Science Advances. https://doi.org/10.1126/sciadv.aef1145

Vancouver

Högström J, Doh HM, Kump A, Petrova B, Wang P, Lee JD, et al. A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer. Science Advances. 2026. doi:10.1126/sciadv.aef1145

BibTeX
@article{Hgstrm2026,
  author = {Högström, Jenny and Doh, Hanna M and Kump, Aidan and Petrova, Boryana and Wang, Peng and Lee, Jonathan D and Koivula, Kaisa and Kozlova, Nina and Cruz, Kayla A and Hong, Su Min and Perea, Camila and Garg, Arjun and Weitman, Michal and Evans, Conor L and Coloff, Jonathan L and Patel, Jaymin M and Wulf, Gerburg M and Collins, Laura C and Kanarek, Naama and Muranen, Taru},
  title = {A noncanonical function of the tyrosine degradation enzyme FAH drives CDK4/6 inhibitor resistance in breast cancer},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aef1145}
}
Start for free →